IFNB1 and neoplasm: Therefore, if we were to consider the disruption in the MHC-I pathway as a hallmark of immune evasion and therapy inefficacy 127, the use of IFNβ, especially under conditions where its expression levels and dynamics are controlled, could render tumor cells visible to the immune system, avoiding primary resistance to subsequent combinatorial immunotherapies.